Fresenius Medical price target raised to $24 from $21 at Truist

Truist analyst David MacDonald raised the firm’s price target on Fresenius Medical to $24 from $21 and keeps a Hold rating on the shares. The firm has updated its estimates after the company’s Q1 results, raising its FY24 and FY25 operating income view by EUR 0.01B to EUR 1.82B and EUR 2.19B, the analyst tells investors in a research note.